<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047839</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-322</org_study_id>
    <nct_id>NCT01047839</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO速, JESPECT速) in a Pediatric Population in Non-endemic Countries</brief_title>
  <official_title>Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO速, JESPECT速) in a Pediatric Population in Non-endemic Countries. Uncontrolled, Open-label Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety profile of IC51 in a pediatric population from
      regions where JEV is not endemic
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination</measure>
    <time_frame>until Day 56</time_frame>
    <description>Rate of subjects with serious adverse events (SAEs) and medically attended AEs up to Day 56 after the first vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Month 7 After the First Vaccination</measure>
    <time_frame>up to Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Solicited Local and Systemic aEs Assessed With a Subject Diary for 7 Consecutive Days After Each Vaccination</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Unsolicited AEs up to Day 56 and up to Month 7 After the First Vaccination</measure>
    <time_frame>up to Day 56 and upt to Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Abnormal Laboratory Parameters up to Day 56 and up to Month 7 After the First Vaccination</measure>
    <time_frame>up to Month 7</time_frame>
    <description>Laboratory parameters were assessed at the Day 28, Day 56 and Month 7 visit. Endpoint reflects abnormal laboratory parameters assessed as clinically significant by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCRs as Defined as Percentage of Subjects With JEV Neutralizing Antibody Titers of PRNT 50 &gt;= 1:10 at Day 56 and Month 7, Measured Using a Validated Plaque Reduction Neutralization Test (PRNT)</measure>
    <time_frame>at Day 56 and Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs for JEV Neutralizing Antibodies Measured Using a Validated PRNT at Day 56 and Month 7</measure>
    <time_frame>at Day 56 and Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCRs at Day 56 and Month 7 Stratified According to Dose Groups and Age Groups</measure>
    <time_frame>at Day 56 and Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs at Day 56 and Month 7 Stratified According to Age Groups</measure>
    <time_frame>at Day 56 and Month 7</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Encephalitis</condition>
  <arm_group>
    <arm_group_label>&gt;=2 months to &lt;3 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt;=3 to &lt;12 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt;=12 to &lt;18 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC51</intervention_name>
    <description>0.25 ml, 2 i.m. vaccinations at Day 0 and 28</description>
    <arm_group_label>&gt;=2 months to &lt;3 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC51</intervention_name>
    <description>0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
    <arm_group_label>&gt;=12 to &lt;18 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC51</intervention_name>
    <description>0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
    <arm_group_label>&gt;=3 to &lt;12 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female healthy children and adolescents aged &gt;=2 months to &lt;18 years at the
             time of first vaccination

          -  Written informed consent by the subject's legal representative(s), according to local
             requirements, and written informed assent of the subject, if applicable

          -  Female subjects: either no childbearing potential or negative pregnancy test. For
             females after menarche willingness to practice a reliable method of contraception.

          -  The subject is planning to travel to an area where JE is endemic after completion of
             the vaccination schedule. Exposure to JE should be avoided until 1 week after the
             second IC51 dose and subjects should return from travel to JE endemic areas before the
             Month 7 visit. The planned travel to JE endemic areas should not interfere with the
             study visits and can take place between Visit 2 + 7 days to Month 7.

        Exclusion Criteria:

          -  Clinical manifestation or history of any Flavivirus disease

          -  Vaccination against JE (except within this protocol), Yellow fever, West Nile virus
             and Dengue at any time prior or during the study

          -  History of immunodeficiency or immunosuppressive therapy

          -  Known HIV, HBV or HCV infection

          -  History of hypersensitivity reactions to other vaccines

          -  Acute febrile infection at each visit during which the subject receives a vaccination

          -  Active or passive immunization within 1 week before and 1 week after each IC51
             vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Ayad, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampa Clinical Research Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Passport Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Deb - The Travel Doctor</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Travel Doctor - TMVC Australia</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danske Laegers Forsknings Center</name>
      <address>
        <city>Soborg</city>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berliner Zentrum f端r Reise- und Tropenmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit辰tsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Akuten Wasa Vaccination</name>
      <address>
        <city>Stockholm</city>
        <zip>11136</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>September 25, 2014</results_first_submitted>
  <results_first_submitted_qc>December 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2014</results_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Japanese Encephalitis Vaccine</keyword>
  <keyword>non-endemic countries</keyword>
  <keyword>to assess immunogenicity of purified inactivated Japanese Encephalitis (JE) vaccine IC51</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>&gt;=2 Months to &lt;3 Years</title>
          <description>IC51 0.25 ml, 2 intramuscular vaccinations at Day 0 and Day 28</description>
        </group>
        <group group_id="P2">
          <title>&gt;=3 to &lt;12 Years</title>
          <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
        </group>
        <group group_id="P3">
          <title>&gt;=12 to &lt;18 Years</title>
          <description>IC51, 0.5 ml, 2 intramuscular vaccinations at Day 0 and 28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>&gt;=2 Months to &lt;3 Years</title>
          <description>IC51 0.25 ml, 2 i.m.vaccinations at Day 0 and Day 28</description>
        </group>
        <group group_id="B2">
          <title>&gt;=3 to &lt;12 Years</title>
          <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
        </group>
        <group group_id="B3">
          <title>&gt;=12 to &lt;18 Years</title>
          <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
            <count group_id="B4" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.81" spread="0.811"/>
                    <measurement group_id="B2" value="6.98" spread="2.417"/>
                    <measurement group_id="B3" value="15.90" spread="1.176"/>
                    <measurement group_id="B4" value="11.62" spread="5.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination</title>
        <description>Rate of subjects with serious adverse events (SAEs) and medically attended AEs up to Day 56 after the first vaccination.</description>
        <time_frame>until Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>&gt;=2 Months to &lt;3 Years</title>
            <description>IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and Day 28</description>
          </group>
          <group group_id="O2">
            <title>&gt;=3 to &lt;12 Years</title>
            <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
          </group>
          <group group_id="O3">
            <title>&gt;=12 to &lt;18 Years</title>
            <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination</title>
          <description>Rate of subjects with serious adverse events (SAEs) and medically attended AEs up to Day 56 after the first vaccination.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="9.9" upper_limit="65.1"/>
                    <measurement group_id="O2" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O3" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Month 7 After the First Vaccination</title>
        <time_frame>up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IC51 0.25 mL</title>
            <description>0.25 mL i.m. vaccinations on Day 0 and Day 28 subjects aged &gt;= 2 months to &lt; 3years</description>
          </group>
          <group group_id="O2">
            <title>IC51 0.5 mL</title>
            <description>0.5 mL i.m. vaccinations on Day 0 and Day 28 subjects &gt;= 3 years to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Month 7 After the First Vaccination</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="26.5"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.7" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="9.9" upper_limit="65.1"/>
                    <measurement group_id="O2" value="18.2" lower_limit="10.8" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Solicited Local and Systemic aEs Assessed With a Subject Diary for 7 Consecutive Days After Each Vaccination</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IC51 0.25 mL</title>
            <description>0.25 mL i.m. vaccinations on Day 0 and Day 28 subjects aged &gt;= 2 months to &lt; 3years</description>
          </group>
          <group group_id="O2">
            <title>IC51 0.5 mL</title>
            <description>0.5 mL i.m. vaccinations on Day 0 and Day 28 subjects &gt;= 3 years to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Subjects With Solicited Local and Systemic aEs Assessed With a Subject Diary for 7 Consecutive Days After Each Vaccination</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any Local after 1st Vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="2.1" upper_limit="48.4"/>
                    <measurement group_id="O2" value="48.9" lower_limit="38.1" upper_limit="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any Systemic after 1st Vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="2.1" upper_limit="48.4"/>
                    <measurement group_id="O2" value="46.0" lower_limit="34.8" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any Local after 2nd Vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.3" upper_limit="51.8"/>
                    <measurement group_id="O2" value="29.4" lower_limit="20.0" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any Systemic after 2nd Vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="2.3" upper_limit="51.8"/>
                    <measurement group_id="O2" value="22.6" lower_limit="14.0" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Unsolicited AEs up to Day 56 and up to Month 7 After the First Vaccination</title>
        <time_frame>up to Day 56 and upt to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IC51 0.25 mL</title>
            <description>0.25 mL i.m. vaccinations on Day 0 and Day 28 subjects aged &gt;= 2 months to &lt; 3years</description>
          </group>
          <group group_id="O2">
            <title>IC51 0.5 mL</title>
            <description>0.5 mL i.m. vaccinations on Day 0 and Day 28 subjects &gt;= 3 years to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Subjects With Unsolicited AEs up to Day 56 and up to Month 7 After the First Vaccination</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any unsolicited AE up to Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                    <measurement group_id="O2" value="29.5" lower_limit="20.3" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE up to Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                    <measurement group_id="O2" value="43.2" lower_limit="32.7" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Abnormal Laboratory Parameters up to Day 56 and up to Month 7 After the First Vaccination</title>
        <description>Laboratory parameters were assessed at the Day 28, Day 56 and Month 7 visit. Endpoint reflects abnormal laboratory parameters assessed as clinically significant by the investigator.</description>
        <time_frame>up to Month 7</time_frame>
        <population>not from all subjects samples were collected, Overall number of participants analyzed were number of participants at Day 0</population>
        <group_list>
          <group group_id="O1">
            <title>IC51 0.25 mL</title>
            <description>0.25 mL i.m. vaccinations on Day 0 and Day 28 subjects aged &gt;= 2 months to &lt; 3years</description>
          </group>
          <group group_id="O2">
            <title>IC51 0.5 mL</title>
            <description>0.5 mL i.m. vaccinations on Day 0 and Day 28 subjects &gt;= 3 years to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Subjects With Abnormal Laboratory Parameters up to Day 56 and up to Month 7 After the First Vaccination</title>
          <description>Laboratory parameters were assessed at the Day 28, Day 56 and Month 7 visit. Endpoint reflects abnormal laboratory parameters assessed as clinically significant by the investigator.</description>
          <population>not from all subjects samples were collected, Overall number of participants analyzed were number of participants at Day 0</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White Blood cells on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCRs as Defined as Percentage of Subjects With JEV Neutralizing Antibody Titers of PRNT 50 &gt;= 1:10 at Day 56 and Month 7, Measured Using a Validated Plaque Reduction Neutralization Test (PRNT)</title>
        <time_frame>at Day 56 and Month 7</time_frame>
        <population>number analyzed = number of subjects achieving seroconversion Overall number of participants analyzed were number of participants at Day 0</population>
        <group_list>
          <group group_id="O1">
            <title>IC51 0.25 mL</title>
            <description>0.25 mL i.m. vaccinations on Day 0 and Day 28 subjects aged &gt;= 2 months to &lt; 3years</description>
          </group>
          <group group_id="O2">
            <title>IC51 0.5 mL</title>
            <description>0.5 mL i.m. vaccinations on Day 0 and Day 28 subjects &gt;= 3 years to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>SCRs as Defined as Percentage of Subjects With JEV Neutralizing Antibody Titers of PRNT 50 &gt;= 1:10 at Day 56 and Month 7, Measured Using a Validated Plaque Reduction Neutralization Test (PRNT)</title>
          <population>number analyzed = number of subjects achieving seroconversion Overall number of participants analyzed were number of participants at Day 0</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="56.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="34.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.6" lower_limit="75.8" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs for JEV Neutralizing Antibodies Measured Using a Validated PRNT at Day 56 and Month 7</title>
        <time_frame>at Day 56 and Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IC51 0.25 mL</title>
            <description>0.25 mL i.m. vaccinations on Day 0 and Day 28 subjects aged &gt;= 2 months to &lt; 3years</description>
          </group>
          <group group_id="O2">
            <title>IC51 0.5 mL</title>
            <description>0.5 mL i.m. vaccinations on Day 0 and Day 28 subjects &gt;= 3 years to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs for JEV Neutralizing Antibodies Measured Using a Validated PRNT at Day 56 and Month 7</title>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.18" lower_limit="105.97" upper_limit="441.00"/>
                    <measurement group_id="O2" value="340.74" lower_limit="269.83" upper_limit="430.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.96" lower_limit="0.00" upper_limit="3214485.72"/>
                    <measurement group_id="O2" value="57.12" lower_limit="38.41" upper_limit="84.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCRs at Day 56 and Month 7 Stratified According to Dose Groups and Age Groups</title>
        <time_frame>at Day 56 and Month 7</time_frame>
        <population>number analyzed = number of subjects achieving seroconversion Overall number of participants analyzed were number of participants at Day 0</population>
        <group_list>
          <group group_id="O1">
            <title>&gt;=2 Months to &lt;3 Years</title>
            <description>IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
IC51: 0.25 ml, 2 i.m. vaccinations at Day 0 and 28</description>
          </group>
          <group group_id="O2">
            <title>&gt;=3 to &lt;12 Years</title>
            <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
IC51: 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
          </group>
          <group group_id="O3">
            <title>&gt;=12 to &lt;18 Years</title>
            <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
IC51: 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
          </group>
        </group_list>
        <measure>
          <title>SCRs at Day 56 and Month 7 Stratified According to Dose Groups and Age Groups</title>
          <population>number analyzed = number of subjects achieving seroconversion Overall number of participants analyzed were number of participants at Day 0</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="56.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="91.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="34.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="20.8" upper_limit="93.9"/>
                    <measurement group_id="O3" value="93.1" lower_limit="78.0" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs at Day 56 and Month 7 Stratified According to Age Groups</title>
        <time_frame>at Day 56 and Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>&gt;=2 Months to &lt;3 Years</title>
            <description>IC51 0.25 ml, 2 intramuscular vaccinations at Day 0 and Day 28</description>
          </group>
          <group group_id="O2">
            <title>&gt;=3 to &lt;12 Years</title>
            <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
          </group>
          <group group_id="O3">
            <title>&gt;=12 to &lt;18 Years</title>
            <description>IC51, 0.5 ml, 2 intramuscular vaccinations at Day 0 and 28</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs at Day 56 and Month 7 Stratified According to Age Groups</title>
          <units>Titer</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.18" lower_limit="105.97" upper_limit="441.0"/>
                    <measurement group_id="O2" value="508.03" lower_limit="267.76" upper_limit="963.90"/>
                    <measurement group_id="O3" value="295.44" lower_limit="235.96" upper_limit="369.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.96" lower_limit="0.00" upper_limit="3214485.72"/>
                    <measurement group_id="O2" value="31.96" lower_limit="0.48" upper_limit="2120.78"/>
                    <measurement group_id="O3" value="60.65" lower_limit="40.72" upper_limit="90.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>&gt;=2 Months to &lt;3 Years</title>
          <description>IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and Day 28</description>
        </group>
        <group group_id="E2">
          <title>&gt;=3 to &lt;12 Years</title>
          <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
        </group>
        <group group_id="E3">
          <title>&gt;=12 to &lt;18 Years</title>
          <description>IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Canal Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Influenza like Illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="25" subjects_affected="19" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Injection Site Itching</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E3" events="42" subjects_affected="31" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hardening</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Excessive Fatigue</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="29" subjects_affected="23" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Initial Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pharyngeal Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Orapharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash Erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Scientist Clinical Research</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>+43 1 206 20 ext 1175</phone>
      <email>katrin.dubischar-kastner@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

